I Holland has launched the Holland Die Condition Monitor (HDCM).
I Holland, the leading specialist manufacturer of tablet tooling for the pharmaceutical and nutraceutical industries, has recently launched the Holland Die Condition Monitor (HDCM).
HDCM is designed to monitor the condition of die bores, for any die type including multi-tips. When used at regular intervals it ensures that optimum life is achieved from dies and helps to prevent the production of damaged tablets.
A high accuracy probe is used, to measure the die bore wear (usually displayed in the form of rings) and when used regularly it can help in the prediction and planning of required expenditure on new die sets
HDCM can be fully integrated with I Holland’s Approve® system for a complete measurement solution, which incorporates tip diameter, barrel diameter, punch concentricity and die bore diameter.
When used as part of I Holland’s recommended PharmaCare® 7-Step Process, a professional punch and die maintenance and storage programme, HDCM assists punch and die users to ensure that critical tooling dimensions have stayed within tolerance following tool polishing or repair work, and helps to ensure proactive monitoring of tooling inventory.
I Holland
Website: www.iholland.co.uk
E-mail: clare.taylor@iholland.co.uk
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.